Increased amygdala responses to sad but not fearful faces in major depression: Relation to mood state and pharmacological treatment

Danilo Arnone, Shane McKie, Rebecca Elliott, Emma J. Thomas, Darragh Downey, G. Juhász, Steve R. Williams, J. F William Deakin, Ian M. Anderson

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

Objective: Increased amygdala response to negative emotions seen in functional MRI (fMRI) has been proposed as a biomarker for negative emotion processing bias underlying depressive symptoms and vulnerability to depressive relapse that are normalized by antidepressant drug treatment. The purpose of this study was to determine whether abnormal amygdala responses to face emotions in depression are related to specific emotions or change in response to antidepressant treatment and whether they are present as a stable trait in medication-free patients in remission. Method: Sixty-two medication-free unipolar depressed patients (38 were currently depressed, and 24 were in remission) and 54 healthy comparison subjects underwent an indirect face-emotion processing task during fMRI. Thirty-two currently depressed patients were treated with the antidepressant citalopram for 8 weeks. Adherence to treatment was evaluated by measuring citalopram plasma concentrations. Results: Patients with current depression had increased bilateral amygdala responses specific to sad faces relative to healthy comparison subjects and non-medicated patients in stable remission. Treatment with citalopram abolished the abnormal amygdala responses to sad faces in currently depressed patients but did not alter responses to fearful faces. Conclusions: Aberrant amygdala activation in response to sad facial emotions is specific to the depressed state and is a potential biomarker for a negative affective bias during a depressive episode.

Original languageEnglish
Pages (from-to)841-850
Number of pages10
JournalAmerican Journal of Psychiatry
Volume169
Issue number8
DOIs
Publication statusPublished - Aug 1 2012

Fingerprint

Amygdala
Emotions
Pharmacology
Depression
Citalopram
Antidepressive Agents
Healthy Volunteers
Therapeutics
Biomarkers
Magnetic Resonance Imaging
Recurrence

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Increased amygdala responses to sad but not fearful faces in major depression : Relation to mood state and pharmacological treatment. / Arnone, Danilo; McKie, Shane; Elliott, Rebecca; Thomas, Emma J.; Downey, Darragh; Juhász, G.; Williams, Steve R.; Deakin, J. F William; Anderson, Ian M.

In: American Journal of Psychiatry, Vol. 169, No. 8, 01.08.2012, p. 841-850.

Research output: Contribution to journalArticle

Arnone, Danilo ; McKie, Shane ; Elliott, Rebecca ; Thomas, Emma J. ; Downey, Darragh ; Juhász, G. ; Williams, Steve R. ; Deakin, J. F William ; Anderson, Ian M. / Increased amygdala responses to sad but not fearful faces in major depression : Relation to mood state and pharmacological treatment. In: American Journal of Psychiatry. 2012 ; Vol. 169, No. 8. pp. 841-850.
@article{75d21fcc365d4f17a84f2613c1102427,
title = "Increased amygdala responses to sad but not fearful faces in major depression: Relation to mood state and pharmacological treatment",
abstract = "Objective: Increased amygdala response to negative emotions seen in functional MRI (fMRI) has been proposed as a biomarker for negative emotion processing bias underlying depressive symptoms and vulnerability to depressive relapse that are normalized by antidepressant drug treatment. The purpose of this study was to determine whether abnormal amygdala responses to face emotions in depression are related to specific emotions or change in response to antidepressant treatment and whether they are present as a stable trait in medication-free patients in remission. Method: Sixty-two medication-free unipolar depressed patients (38 were currently depressed, and 24 were in remission) and 54 healthy comparison subjects underwent an indirect face-emotion processing task during fMRI. Thirty-two currently depressed patients were treated with the antidepressant citalopram for 8 weeks. Adherence to treatment was evaluated by measuring citalopram plasma concentrations. Results: Patients with current depression had increased bilateral amygdala responses specific to sad faces relative to healthy comparison subjects and non-medicated patients in stable remission. Treatment with citalopram abolished the abnormal amygdala responses to sad faces in currently depressed patients but did not alter responses to fearful faces. Conclusions: Aberrant amygdala activation in response to sad facial emotions is specific to the depressed state and is a potential biomarker for a negative affective bias during a depressive episode.",
author = "Danilo Arnone and Shane McKie and Rebecca Elliott and Thomas, {Emma J.} and Darragh Downey and G. Juh{\'a}sz and Williams, {Steve R.} and Deakin, {J. F William} and Anderson, {Ian M.}",
year = "2012",
month = "8",
day = "1",
doi = "10.1176/appi.ajp.2012.11121774",
language = "English",
volume = "169",
pages = "841--850",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "8",

}

TY - JOUR

T1 - Increased amygdala responses to sad but not fearful faces in major depression

T2 - Relation to mood state and pharmacological treatment

AU - Arnone, Danilo

AU - McKie, Shane

AU - Elliott, Rebecca

AU - Thomas, Emma J.

AU - Downey, Darragh

AU - Juhász, G.

AU - Williams, Steve R.

AU - Deakin, J. F William

AU - Anderson, Ian M.

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Objective: Increased amygdala response to negative emotions seen in functional MRI (fMRI) has been proposed as a biomarker for negative emotion processing bias underlying depressive symptoms and vulnerability to depressive relapse that are normalized by antidepressant drug treatment. The purpose of this study was to determine whether abnormal amygdala responses to face emotions in depression are related to specific emotions or change in response to antidepressant treatment and whether they are present as a stable trait in medication-free patients in remission. Method: Sixty-two medication-free unipolar depressed patients (38 were currently depressed, and 24 were in remission) and 54 healthy comparison subjects underwent an indirect face-emotion processing task during fMRI. Thirty-two currently depressed patients were treated with the antidepressant citalopram for 8 weeks. Adherence to treatment was evaluated by measuring citalopram plasma concentrations. Results: Patients with current depression had increased bilateral amygdala responses specific to sad faces relative to healthy comparison subjects and non-medicated patients in stable remission. Treatment with citalopram abolished the abnormal amygdala responses to sad faces in currently depressed patients but did not alter responses to fearful faces. Conclusions: Aberrant amygdala activation in response to sad facial emotions is specific to the depressed state and is a potential biomarker for a negative affective bias during a depressive episode.

AB - Objective: Increased amygdala response to negative emotions seen in functional MRI (fMRI) has been proposed as a biomarker for negative emotion processing bias underlying depressive symptoms and vulnerability to depressive relapse that are normalized by antidepressant drug treatment. The purpose of this study was to determine whether abnormal amygdala responses to face emotions in depression are related to specific emotions or change in response to antidepressant treatment and whether they are present as a stable trait in medication-free patients in remission. Method: Sixty-two medication-free unipolar depressed patients (38 were currently depressed, and 24 were in remission) and 54 healthy comparison subjects underwent an indirect face-emotion processing task during fMRI. Thirty-two currently depressed patients were treated with the antidepressant citalopram for 8 weeks. Adherence to treatment was evaluated by measuring citalopram plasma concentrations. Results: Patients with current depression had increased bilateral amygdala responses specific to sad faces relative to healthy comparison subjects and non-medicated patients in stable remission. Treatment with citalopram abolished the abnormal amygdala responses to sad faces in currently depressed patients but did not alter responses to fearful faces. Conclusions: Aberrant amygdala activation in response to sad facial emotions is specific to the depressed state and is a potential biomarker for a negative affective bias during a depressive episode.

UR - http://www.scopus.com/inward/record.url?scp=84864813626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864813626&partnerID=8YFLogxK

U2 - 10.1176/appi.ajp.2012.11121774

DO - 10.1176/appi.ajp.2012.11121774

M3 - Article

C2 - 22854930

AN - SCOPUS:84864813626

VL - 169

SP - 841

EP - 850

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 8

ER -